Abstract
Background:
Intraprostatic injection of ethanol has been previously tested in clinical trials as a potential treatment of BPH, with variable outcomes. As evident from animal studies, the inconsistency was owing to various degrees of ethanol backflow along the needle tract. In acute canine experiments, we previously documented that using convection enhanced delivery (CED) eliminates backflow and improves ethanol distribution. The goal of this study was to compare the diffusion pattern between a microporous hollow fiber catheter (MiHFC) and a standard needle in human prostates from organ donors.
Methods:
Prostates were harvested from cadaveric organ donors immediately after removal of organs for transplant. After trimming off excess fat and weighing, prostates were injected with absolute ethanol. The total injected volume was 25% of the calculated prostate volume. One lateral lobe was injected using a single lumen 21-gauge control needle. The contralateral lobe was injected with the same volume but using a MiHFC. Immediately after injection, prostates were fixed en bloc in 10% neutral-buffered formalin, and then sectioned. Three-dimensional reconstruction was performed to determine lesion volume based on hematoxylin- and eosin-stained cross-sections.
Results:
Three fresh human prostates were harvested and injected. The time from harvest to intraprostatic injection was 15–35 min. The lesion created by the MiHFC was 1.14±0.52 cm3, whereas that from the control needle was 0.28±0.10 cm3 (P=0.038). No backflow was observed along the needle tract of the MiHFC.
Conclusions:
This study shows that freshly harvested human prostates can be used to evaluate new treatments using intraprostatic injection. Similar to in vivo canine experiments, the ethanol lesion sizes were significantly bigger with the use of a MiHFC when compared with a standard single lumen needle.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 4 print issues and online access
$259.00 per year
only $64.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Zvara P, Karpman E, Stoppacher R, Esenler AC, Plante MK . Ablation of canine prostate using transurethral intraprostatic absolute ethanol injection. Urology 1999; 54: 411–415.
Andersson KE . Intraprostatic injections for lower urinary tract symptoms treatment. Curr Opin Urol 2015; 25: 12–18.
Falahatkar S, Shahab E, Gholamjani Moghaddam K, Kazemnezhad E . Transurethral intraprostatic injection of botulinum toxin type A for the treatment of chronic prostatitis/chronic pelvic pain syndrome: results of a prospective pilot double-blind and randomized placebo-controlled study. BJU Int 2014 (doi:10.1111/bju.12951).
Wientjes MG, Zheng JH, Hu L, Gan Y, Au JL . Intraprostatic chemotherapy: distribution and transport mechanisms. Clin Cancer Res 2005; 11: 4204–4211.
Andersson KE . Treatment of lower urinary tract symptoms: agents for intraprostatic injection. Scand J Urol 2013; 47: 83–90.
Grise P, Plante M, Palmer J, Martinez-Sagarra J, Hernandez C, Schettini M et al. Evaluation of the transurethral ethanol ablation of the prostate (TEAP) for symptomatic benign prostatic hyperplasia (BPH): a European multi-center evaluation. Eur Urol 2004; 46: 496–501.
Buchholz NN, Andrews HO, Plante MK . Transurethral ethanol ablation of prostate. J Endourol 2004; 18: 519–524.
Plante MK, Gross AL, Kliment J, Kida M, Zvara P . Intraprostatic ethanol chemoablation via transurethral and transperineal injection. BJU Int 2003; 91: 94–98.
Plante MK, Gross AL, Folsom JB, Zvara P . Diffusion properties of transurethral intraprostatic injection. BJU Int 2004; 94: 1384–1388.
King BJ, Plante MK, Kida M, Mann-Gow TK, Odland R, Zvara P . Comparison of intraprostatic ethanol diffusion using a microporous hollow fiber catheter versus a standard needle. J Urol 2012; 187: 1898–1902.
Oh S, Odland R, Wilson SR, Kroeger KM, Liu C, Lowenstein PR et al. Improved distribution of small molecules and viral vectors in the murine brain using a hollow fiber catheter. J Neurosurg 2007; 107: 568–577.
Oh S, Tsai AK, Ohlfest JR, Panoskaltsis-Mortari A, Vallera DA . Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain. J Neurosurg 2011; 114: 1662–1671.
Donnell RF . Minimally invasive therapy of lower urinary tract symptoms. Urol Clin North Am 2009; 36: 497–509.
Kovi J, Mostofi FK, Heshmat MY, Enterline JP . Large acinar atypical hyperplasia and carcinoma of the prostate. Cancer 1988; 61: 555–561.
Chung B, Simmer G, Brooks J . Anatomy of the lower urinary tract and male genitalia. In: Wein A (ed). Campbell-Walsh Urology, 10th edn. Saunders: Philadelphia, PA, USA, 2012; pp 56–57.
Lieberman DM, Laske DW, Morrison PF, Bankiewicz KS, Oldfield EH . Convection-enhanced distribution of large molecules in gray matter during interstitial drug infusion. J Neurosurg 1995; 82: 1021–1029.
Bobo RH, Laske DW, Akbasak A, Morrison PF, Dedrick RL, Oldfield EH . Convection-enhanced delivery of macromolecules in the brain. Proc Nati Acad Sci USA 1994; 91: 2076–2080.
Laske DW, Morrison PF, Lieberman DM, Corthesy ME, Reynolds JC, Stewart-Henney PA et al. Chronic interstitial infusion of protein to primate brain: determination of drug distribution and clearance with single-photon emission computerized tomography imaging. J Neurosurg 1997; 87: 586–594.
Talwar GL, Pande SK . Injection treatment of enlarged prostate. Br J Surg 1966; 53: 421–427.
Angell JC . Treatment of benign prostatic hyperplasia by phenol injection. Br J Urol 1969; 41: 735–738.
Li Y, Zhao Q, Dong L . Efficacy and safety of ultrasound-guided transrectal ethanol injection for the treatment of benign prostatic hyperplasia in patients with high-risk comorbidities: a long-term study at a single tertiary care institution. Urology 2014; 83: 586–591.
Rud E, Klotz D, Rennesund K, Baco E, Berge V, Lien D et al. Detection of the index tumor and tumor volume in prostate cancer using T2w and DW MRI alone. BJU Int 2014; 114: E32–E42.
Baco E, Ukimura O, Rud E, Vlatkovic L, Svindland A, Aron M et al. Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. Eur Urol 2014; 67: 787–794.
Pokorny MR, de Rooij M, Duncan E, Schroder FH, Parkinson R, Barentsz JO et al. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies. Eur Urol 2014; 66: 22–29.
Oelke M, Bachmann A, Descazeaud A, Emberton M, Gravas S, Michel MC et al. EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction. Eur Urol 2013; 64: 118–140.
Goya N, Ishikawa N, Ito F, Ryoji O, Tokumoto T, Toma H et al. Ethanol injection therapy of the prostate for benign prostatic hyperplasia: preliminary report on application of a new technique. J Urol 1999; 162: 383–386.
Ditrolio J, Patel P, Watson RA, Irwin RJ . Chemo-ablation of the prostate with dehydrated alcohol for the treatment of prostatic obstruction. J Urol 2002; 167: 2100–2103 discussion 2103-2104.
Acknowledgements
We thank TwinStar Medical, Minneapolis, MN for providing us with the MiHFC technology.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
King, B., Mann-Gow, T., Kida, M. et al. Intraprostatic ethanol diffusion: comparison of two injection methods using ex vivo human prostates. Prostate Cancer Prostatic Dis 18, 237–241 (2015). https://doi.org/10.1038/pcan.2015.24
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/pcan.2015.24